Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARsen

Financiado

Cerrado

Senolytic CAR T cells as novel therapeutic concept for solid tumors and senescen...

Senolytic CAR T cells as novel therapeutic concept for solid tumors and senescence associated diseases. The adoptive transfer of T cells expressing CD19-directed chimeric antigen receptors (CARs) has yielded remarkable efficacy in patients with hematological B-cell malignancies. CARs are a class of synthetic receptors that reprogram... ver más

31/12/2026

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-18

ERC-2020-STG: ERC STARTING GRANTS

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

1.82M€ | Lider

IGARLE

283.96K€ | Participante

JSV INFORMATICA I COMUNICACI...

309.04K€ | Participante

RIBATE ASOCIADOS, S.L.

422.60K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SweetCAR CAR T cell therapy targeting carbohydrates in cancer 150K€ Cerrado

CNS2023-143983 Inmunidad, infección e inmunoterapia 200K€ Cerrado

ARMOR-T Armoring multifunctional T cells for cancer therapy 2M€ Cerrado

Exh-Res-CART Exhaustion resistant CAR T cells for the treatment of solid... 161K€ Cerrado

INCITE Immune Niches for Cancer ImmunoTherapy Enhancement 4M€ Cerrado

Immune-senescence Dual targeting of senescence and tumor immunity for cancer t... 2M€ Cerrado

Duración del proyecto: 71 meses Fecha Inicio: 2021-01-18
Fecha Fin: 2026-12-31

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The adoptive transfer of T cells expressing CD19-directed chimeric antigen receptors (CARs) has yielded remarkable efficacy in patients with hematological B-cell malignancies. CARs are a class of synthetic receptors that reprogram T cell specificity, function and metabolism. Engineered T cells are applicable in principle to other cancers and diseases, but clinical success will critically depend on further progress to overcome current limitations such as antigenic heterogeneity or impaired T cell trafficking and function. We propose to develop CAR T cells targeting senescent cells as a novel therapeutic concept for cancer and senescence-associated diseases. Cellular senescence is a stress-response program characterized by stable cell cycle arrest that serves as a potent tumor-suppressive mechanism. Conversely, accumulation of senescent cells generates a chronic inflammatory milieu, which contributes to a plethora of pathologies, such as liver or lung fibrosis and can even promote tumor progression. Our preliminary data demonstrate that CAR T cells can efficiently clear senescent cells, providing therapeutic benefit in a murine model of liver fibrosis. We thus firmly believe that senolytic CAR T cells have broad therapeutic potential. To this end, we will apply innovative engineering strategies to develop modular CAR designs tailored to senescence-specific requirements. We will determine safety and efficacy of senolytic CAR T cells in murine models of cellular senescence and solid tumors. Importantly, we will evaluate combined treatment approaches of senescence-inducing therapies with CAR T cells targeting senescent and proliferating tumor cells. Finally, we will investigate engineering tools to optimally direct senolytic CAR activity to mediate durable tumor regression. This project combines two emerging concepts of anticancer therapies and goes beyond current applications of CAR therapies. The efforts may lead to promising new therapeutic avenues.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores